0001802768 false X0 0001802768 2020-08-19 2020-08-19 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):

August 19, 2020

 

Royalty Pharma plc

(Exact Name of Registrant as Specified in its Charter)

 

England and Wales   001-39329   Not Applicable

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

     

110 East 59th Street

New York, New York

      10022

(Address of Principal Executive

Offices)

      (Zip Code)

Registrant’s telephone number, including area code: (212) 883-0200

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:

 

Title of each class   Trading symbol(s)  

Name of each exchange on which

registered

Class A Ordinary Shares, par value $0.0001 per share

  RPRX   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

Item 2.02 Results of Operations and Financial Condition.

 

On August 19, 2020, Royalty Pharma plc (the “Company”) announced its intent to offer, subject to market and other conditions, senior unsecured notes (the “Notes”) in a private offering only to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A and Regulation S under the Securities Act of 1933, as amended. The Notes will be guaranteed on a senior unsecured basis by Royalty Pharma Holdings Ltd. The Company intends to use the net proceeds from the Notes, together with available cash on hand, to repay its existing Term Loan and Term Loan B facilities and to pay fees and expenses incurred in connection with the offering, with any remainder to be used for general corporate purposes.

 

A copy of the press release announcing the offering of the Notes is being furnished as Exhibit 99.1 attached hereto and is incorporated by reference herein.

 

In connection with the offering of the Notes, the Company provided certain unaudited pro forma financial information to prospective eligible investors in a preliminary offering memorandum, dated August 19, 2020 (the “Offering Memorandum”). The Company is furnishing on this Current Report on Form 8-K such unaudited pro forma financial information excerpted from the Offering Memorandum, which is incorporated herein by reference as Exhibit 99.2.

 

The unaudited pro forma information does not purport to be indicative of the Company’s results of operations or financial position had the relevant transactions occurred on the dates assumed and does not project the Company’s results of operations or financial position for any future period or future date.

 

The information furnished pursuant to this Item 2.02, including Exhibits 99.1 and 99.2, shall not be deemed to be “filed” for purposes of Section 18 of, or otherwise regarded as filed under, the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference into any filing under the Securities Act or in the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

 

Item 9.01. Financial Statements and Exhibits

 

  (d) Exhibits

 

     
99.1   Press Release dated August 19, 2020.
99.2   Unaudited Pro Forma Financial Information.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: August 19, 2020

 

  ROYALTY PHARMA PLC
   
     
  By:

/s/ Pablo Legorreta

    Pablo Legorreta
    Chief Executive Officer

 

 

 

Exhibit 99.1

 

ROYALTY PHARMA ANNOUNCES LAUNCH OF SENIOR NOTES OFFERING

 

NEW YORK (NY) - August 19, 2020Royalty Pharma plc announced today that it intends to offer, subject to market and other conditions, senior unsecured notes in multiple tranches (the “Notes”) in a private offering exempt from registration in accordance with Rule 144A and Regulation S under the Securities Act of 1933, as amended (the “Securities Act”). The Notes will be guaranteed on a senior unsecured basis by Royalty Pharma Holdings Ltd.

 

Royalty Pharma intends to use the net proceeds from the Notes, together with available cash on hand, to repay its existing Term Loan A and Term Loan B facilities and to pay fees and expenses incurred in connection with the offering, with any remainder to be used for general corporate purposes.

 

The Notes are being offered only to persons reasonably believed to be qualified institutional buyers in reliance upon Rule 144A under the Securities Act and, outside the United States, only to non-U.S. persons pursuant to Regulation S under the Securities Act. The Notes have not been registered under the Securities Act or any state securities laws and may not be offered or sold in the United States absent an effective registration statement or an applicable exemption from registration requirements under the Securities Act or any state securities laws.

 

This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities, nor does it constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale is unlawful.

 

About Royalty Pharma

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 45 commercial products, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, and Vertex’s Kalydeco, Symdeko and Trikafta, and four development-stage product candidates.

 

Forward-Looking Statements

This press release contains statements that constitute “forward-looking statements” as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the company’s opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of our strategies, financing plans, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project,” “expect,” “may,” “will,” “would,” “could” or “should,” the negative of these terms or similar expressions. Forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to the company. However, these forward-looking statements are not a guarantee of our performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, and other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the company’s control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this document are made only as of the date hereof. The company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.

 

Royalty Pharma Investor Relations and Communications:

+1 (212) 883-0200

ir@royaltypharma.com

 

 

Exhibit 99.2

 

 

Unaudited pro forma financial information

 

The unaudited pro forma condensed consolidated statements of comprehensive income for the six months ended June 30, 2020 present our consolidated results of operations after giving effect to:

 

·the Reorganization Transactions;

 

·the sale by us of 89,333,920 shares of our Class A ordinary shares, of which 71,652,250 and 17,681,670 shares were offered by the Company and selling shareholders, respectively pursuant to a registration statement on Form S-1 filed with the U.S. Securities and Exchange Commission ("SEC") at a price to the public of $28.00 per share, including the exercise in full of the underwriters' option to purchase 11,652,250 additional Class A ordinary shares from us; and

 

·the Exchange Agreement entered into by RP Holdings, the Continuing Investors Partnerships and the Continuing Investors in connection with the offering that provides that the Continuing International Investors Partnership promptly distribute to its holders substantially all of the RP Holdings Class B ordinary shares or depository receipts that represent such shares (the “RP Holdings Class B Interests”) it holds which were exchanged for our Class A ordinary shares.

 

The statements of comprehensive income for the six months ended June 30, 2020 present the consolidated results of operations to give pro forma effect to all transactions identified above as if all such events had been completed as of January 1, 2020.

 

The unaudited pro forma consolidated financial information has been prepared by management and is based on the historical financial statements of Royalty Pharma plc, Old RPI prior to the Exchange Date, and its successor for financial reporting purposes, RPI, from the Exchange Date until completion of our initial public offering, and their consolidated subsidiaries and the assumptions and adjustments described in the notes to the unaudited pro forma financial information below. The presentation of the unaudited pro forma financial information is prepared in conformity with Article 11 of Regulation S-X.

 

The historical financial information of Royalty Pharma plc, Old RPI, RPI and their consolidated subsidiaries has been derived from the consolidated financial statements and accompanying notes included elsewhere in this prospectus.

 

We based the pro forma adjustments on available information and on assumptions that we believe are reasonable under the circumstances in order to reflect, on a pro forma basis, the impact of the relevant transactions on the historical financial information of Royalty Pharma plc, Old RPI, RPI and their consolidated subsidiaries. Refer to the notes to the unaudited pro forma financial information below for a discussion of assumptions applied. The pro forma adjustments represent only those transactions which are directly attributable to this offering, factually supportable, and expected to have a continuing impact on our results of operations. The unaudited pro forma financial information does not purport to be indicative of our results of operations or financial position had the relevant transactions occurred on the dates assumed and does not project our results of operations or financial position for any future period or date.

 

 

1 

 

Unaudited Pro Forma Consolidated Statement of Comprehensive Income
For the six months ended June 30, 2020

 

   Six Months Ended June 30, 2020
   Historical        Pro Forma
   Royalty Pharma plc and Subsidiaries  Pro Forma Adjustments  Royalty Pharma plc and Subsidiaries
   ($ in thousands except per share amounts) (unaudited)
Total income and revenues            
Income from financial royalty assets   $937,021   $      $937,021 
Revenue from intangible royalty assets    68,428           68,428 
Other royalty income    6,362           6,362 
Total income and other revenues    1,011,811           1,011,811 
Operating expenses                  
Research and development funding expense    13,415           13,415 
Provision for changes in expected cash flows from financial royalty assets    135,290           135,290 
Amortization of intangible assets    11,466           11,466 
General and administrative expenses    80,864    28,923   (a)   109,787 
Total operating expenses    241,035    28,923   (a)   269,958 
Operating income    770,776    (28,923)  (a)   741,853 
Other expense/(income)                  
Equity in loss/(earnings) of non-consolidated affiliates    (20,218)   (3,044)  (f)   (23,262)
Interest expense    87,773    (4,355)  (b)   83,418 
Other non-operating income, net    (7,851)   (10,900)  (b)   (18,751)
Total other expense/(income), net    59,704    (18,299)  (a),(b),(f)   41,405 
Consolidated net income before tax    711,072    (10,624)  (a),(b),(f)   700,448 
Income tax benefit (expense)                
Consolidated net income    711,072    (10,624)  (a),(b),(f)   700,448 
Less: Net income attributable to non-controlling interest    (197,758)   (195,942)  (c)   (393,700)
Net income attributable to controlling interest    513,314    (206,566)  (a),(b),(c), (f)   306,748 
Other comprehensive income/(loss):                  
Reclassification of loss on interest rate swaps included in net income    4,066    (4,066)  (b)    
Change in unrealized movement on available for sale debt securities    59,674           59,674 
Other comprehensive income    63,740    (4,066)  (b)   59,674 
Comprehensive income    577,054    (210,632)  (a),(b),(c),
(f)
   366,422 
Less: Other comprehensive income/(loss) attributable to non-controlling interest    (11,296)   (18,734)  (b)(c)   (30,030)
Comprehensive income attributable to controlling interest    565,758    (229,366)  (a),(b),(c),
(f)
   336,392 
Pro forma earnings per share:                  
Basic   $0.09        (d)  $0.84 
Diluted   $0.09        (d)  $0.84 
Pro forma number of shares used in computing earnings per share:                  
Basic    353,979        (d)   365,899 
Diluted    353,980        (d)   365,899 

 

 

2 

 

_______________

(a)Reflects the recognition of incremental Operating and Personnel Payments of $29.6 million for the Company and a reduction of $0.7 million for the amount attributable to RPI US Partners, LP; RPI US Partners II, LP; RPI International Partners, LP; and RPI International Partners II, LP (the “Legacy Investors Partnerships”), for the six months ended June 30, 2020. The Operating and Personnel Payments are calculated according to the formula described in the Management Agreement. The Operating and Personnel Payment for Old RPI, an obligation of the Legacy Investors Partnerships as the holder of a noncontrolling interest in Old RPI, for which the expense is reflected in RPI’s consolidated statements of income, is calculated as the greater of $1 million per quarter and 0.3125% of Royalty Investments (as defined therein).

 

(b)Reflects the repayment of the RPI Finance Trust (“RPIFT”) senior secured credit facilities, the issuance of the new RPI Term Loan A and Term Loan B facilities (the “Term Loans”), including deferred financing fees, and the termination of the interest rate swaps that were unwound in connection with the refinancing. The terms of the New Term Loans are as follows, with required annual amortization payments of $160 million and $28.4 million associated with Term Loan A and Term Loan B, respectively:

 

Credit Facility 

Principal 

Interest 

Maturity 

  ($ thousands)
RPI Term Loan A Facility $3,200,000 L + 150 bps 2025
RPI Term Loan B Facility $2,840,000 L + 175 bps 2027

 

(c)As a result of our initial public offering and the Reorganization Transactions, we own approximately 50% of the economic interest of Old RPI (excluding the RP Holdings Class C Special Interest).

 

The net income and other comprehensive income attributable to non-controlling interests from the Exchange Date relates to the following: (i) 18% ownership of Old RPI held by the Legacy Investors Partnerships and (ii) a de minimis percentage is attributable to non-controlling interest holders of certain subsidiaries of Old RPI, which has existed in the historical financial statements since 2011. Immediately following the completion of our initial public offering a new non-controlling interest was created which is attributable to the RP Holdings Class B Interests held indirectly by the Continuing Investors, which represent a 40% ownership interest in RP Holdings and are exchangeable for Class A ordinary shares of Royalty Pharma plc. Pro forma adjustments to Net income attributable to non-controlling interest for the six months ended June 30, 2020, by interest holder are shown below.

 

Adjustments for Net income attributable to non-controlling interests:  Pro Forma Six Months Ended June 30, 2020
   ($ thousands)
(unaudited)
Legacy Investors Partnerships   $17,902 
Continuing Investors Partnerships(1)    178,040 
Total pro forma adjustment for net income attributable to non-controlling interests   $195,942 

 

(1) Related to the Continuing Investors Partnerships' ownership of approximately 40% in RP Holdings through their ownership of the RP Holdings Class B Interests.

 

(d)Historical basic and diluted earnings per share were only presented for the period from June 16, 2020 through June 30, 2020, representing earnings per share for the period subsequent to our initial public offering. The basic and diluted pro forma earnings per Class A ordinary share represent net income attributable to controlling interest divided by a combination of Class A ordinary shares issued in our initial public offering and Class A ordinary shares exchanged by the Continuing International Investors Partnership in exchange for their RP Holdings Class B Interests as described in “Organizational Structure.” Pro forma RP Holdings Class B interests of 241,207,425 were evaluated under the if-converted method for potential dilutive effects and were determined to be antidilutive. The table below presents the computation of pro forma basic and dilutive earnings per share (“EPS”) for the controlling interest.

 

3 

 

 

Earnings per Ordinary Share  Pro Forma Six Months Ended June 30, 2020
   ($ thousands, except share-related amounts) (unaudited)
Numerator:     
Net income attributable to controlling interest—basic and diluted   $306,748 
Denominator:     
Weighted average Class A ordinary shares outstanding—basic and diluted    365,899,235 
Basic earnings per share   $0.84 
Diluted earnings per share   $0.84 

 

(f)Reflects the contribution of the Legacy Special Limited Partnership Interest in the Legacy Investors Partnerships (the “Legacy SLP Interest”) that arose as part of the Reorganization Transactions. The Legacy SLP Interest entitles us to the equivalent of performance distribution payments that would have been paid to the general partner of the Legacy Investors Partnerships and an income allocation on a similar basis. The income allocation attributable to Royalty Pharma plc is equal to the general partner’s former contractual rights to the income of the Legacy Investors Partnerships. The adjustment reflects an increase to Equity in (earnings)/loss of non-consolidated affiliates due to the new equity method investment in the Legacy Investors Partnerships and an increase to the Investment in non-consolidated affiliates.

 

 

 

4 

 

v3.20.2
Cover
Aug. 19, 2020
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 19, 2020
Entity File Number 001-39329
Entity Registrant Name Royalty Pharma plc
Entity Central Index Key 0001802768
Entity Incorporation, State or Country Code X0
Entity Address, Address Line One 110 East 59th Street
Entity Address, City or Town New York
Entity Address, State or Province NY
Entity Address, Postal Zip Code 10022
City Area Code 212
Local Phone Number 883-0200
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Class A Ordinary Shares, par value $0.0001 per share
Trading Symbol RPRX
Security Exchange Name NASDAQ
Entity Emerging Growth Company false